NEW YORK (GenomeWeb News) – Swiss molecular diagnostics firm Biocartis has raised €10 million ($14.9 million) in a Series A financing round that included a handful of European investment firms.
The Lausanne, Switzerland-based firm is developing a multiplex, molecular diagnostics platform that will be able to quantify and amplify bio-analytes, such as proteins, nucleic acids, and small molecules. The firm said that it will use the proceeds from the private offering to develop a commercial version of its proprietary platform, as well as its first prototype assays.
The Series A round was led by Aescap Ventures, which is based in Amsterdam. Other investors included Biovest (Belgium), KBC Private Equity (Belgium), Advent Venture Partners (UK), and Benaruca (Luxembourg). Each of the investors has a representative on Biocartis' board of directors.
Biocartis was founded in 2007. It was founded by its President, Rudi Pauwels, who previously co-founded Tibotec, Virco, and Galapagos Genomics.